Iberdomide - Bristol Myers Squibb
Alternative Names: BMS 986382; CC-220; IBERLatest Information Update: 05 Sep 2024
At a glance
- Originator Celgene Corporation
- Developer Bristol-Myers Squibb; Celgene Corporation
- Class Anti-inflammatories; Antineoplastics; Isoindoles; Piperidones; Skin disorder therapies; Small molecules
- Mechanism of Action Ubiquitin protein ligase complex modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Multiple myeloma
- Phase I B-cell lymphoma
- No development reported Lymphoma
- Discontinued Atopic dermatitis; Cutaneous lupus erythematosus; Follicular lymphoma; Sarcoidosis; Systemic lupus erythematosus; Systemic scleroderma
Most Recent Events
- 22 Aug 2024 Hackensack Meridian Health re-initiates phase-I/II clinical trials in Multiple myeloma (Combination therapy, First-line therapy) in USA (PO) (NCT05199311)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy, Second-line therapy or greater) in France (PO)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy, Second-line therapy or greater) in Germany (PO)